HISTORY
Alliance was founded in 1996 by John Dawson, Chief Executive and began trading in 1998. Since then the company has grown consistently with a strong acquisition and value extraction programme.
2011
- Acquired the UK marketing rights to the brands Quinoderm® and Ceanel® from Ferndale Pharmaceuticals Limited. Quinodern is an OTC acne treatment and Ceanel is a shampoo used in the treatment of scalp psoriasis.
- Acquired the UK and Irish rights to the brands Anbesol® and Ashton & Parsons® from Reckitt Benckiser. Anbesol is used to treat mouth ulcers, teething pains and denture irritation. Ashton & Parsons is used in infants for the symptomatic relief of pain and stomach upset caused by teething.
- Acquired the UK marketing rights to six products from Beacon Pharmaceuticals Limited. The majority of these sales and margin for this portfolio relates to Rizuderm (isotretinoin), which is used in the treatment of severe acne and fits well in Alliance's dermatology business.
2010
Acquired the trade and certain assets of Cambridge Laboratories. There were 18 products in this acquisition, including three growing oncology products.
2009
Acquired worldwide rights to the brands BUCCASTEM® for nausea and vomiting and TIMODINE® for severe nappy rash from Reckitt Benckiser.
2008
Acquired the brand PAVACOL-D® from William Ransom & Sons. PAVACOL-D is a cough suppressant that is suitable for use by diabetics as it is sugar free.
2007
In a joint venture with a local distributor acquired the rights to market FORCEVAL® in China and the Far East.
2006
Saw the largest number of acquisition deals yet achieved in a single year:
- Alliance acquired the UK rights to HYDROMOL, a family of cream, emollient and ointment products for various dry skin conditions, such as eczema bringing critical mass to the dermatology portfolio.
- Acquisition of DERMAMIST® UK marketing rights from Caraderm, a spray used for dry skin conditions, complementing the dermatology range
- The acquisition of the well established oral steroid DELTACORTRIL, the oral anti-histamine ATARAX and TERRACORTRIL from Pfizer gave Alliance the UK rights to additional products for the dermatology range and other indications.
- 2006 also saw the acquisition of PERMITABS® in the UK and Eire for eczematous wounds from Derma UK.
- To complete its sixth acquisition deal in 2006, Alliance acquired the UK rights to SYNTOMETRINE from Novartis. Alliance has marketed and distributed SYNTOMETRINE in the UK since 1998 under a distribution agreement, This deal has given Alliance ownership of the UK marketing rights.
2005
Integrating acquistions acquired late in 2004.
2004
- Acquired the assets of Unigreg Ltd giving Alliance significant UK turnover and an international network of distributors with FORCEVAL.
- CollaGenex Inc divested the rights to PERIOSTAT in the UK, Europe and various international territories to Alliance.
2004 saw three further acquisitions:
- Dermapharm Ltd gaining the rights to four niche dermatologicals
- In addition the nutritional supplement FORCEVAL and PERIOSTAT for periodontitis was acquired.
2003
Heralded an important milestone when Alliance floated on the Alternative Investment Market (AIM) of the London Stock Exchange.
2002
Acquired two dermatological brands from Procter and Gamble and expanded into the Republic of Ireland with the acquisition of the rights to NU-SEALS from Eli Lilly and Company.
2001
Alliance acquired DISTAMINE from Eli Lilly and later in the year acquired SYMMETREL and SLOW K® from Novartis.
1999
Alliance acquired the rights to NASEPTIN®, BROFLEX®, BIORPHEN® and PRAGMATAR from Bioglan.
1998
Alliance entered into a fostering arrangement with Novartis and took over the marketing and distribution of 16 speciality prescription brands.